Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Potential Link Between Industrial Pollutants and Acute Myeloid Leukemia Examined

March 8, 2019
By John Schieszer
News
Article

A recent study evaluated whether living in an industrial city could be an important risk factor for developing AML.

Living in an industrial city with exposure to materials/pollution from industrial plants may be an important risk factor for developing acute myeloid leukemia (AML), according to a study published online in the journal Cancer.

Feras M. Ghazawi, MD, PhD, of the University of Ottawa in Ontario, Canada, and colleagues analyzed the incidence and geographic distribution of AML in Canada from 1992 to 2010 using three independent population‐based cancer registries. A total of 18,085 patients were identified during this timeframe, with an AML incidence of 30.61 cases per million individuals per year. The incidence and mortality rates were then examined at the levels of province/territory, city, and postal code.

Five industrial cities in Ontario had incidence rates that were significantly higher than the national average (Sarnia, Sault Ste. Marie, Thunder Bay, St. Catharines, and Hamilton). In one specific postal code in Sarnia, Ontario, the incidence rate was 106.81 cases per million individuals per year, which is more than three times higher than the national average.

“The pollution from local oil refineries and chemical plants in Sarnia may be implicated as a risk factor for AML in that city. Analysis of mortality rates at the province and city levels corroborated the findings from the incidence data,” concluded the authors.

Felipe Samaniego, MD, an associate professor of Lymphoma/Myeloma at MD Anderson Cancer Center in Houston, said this report independently reaches the conclusion that industry centers are associated with the emergence of a higher number of AML cases. However, in some ways it raises more questions than answers, he said.

“It is an area of immensely important and fruitful research. We now have the capacity to look at sum experiences of all studies that identify hotspots of cancers and analyze what is common to most areas that leads to a high incidence of AML,” Samaniego told Cancer Network. “The report implies that pollution is the culprit for AML; however, pollution may be only an associated factor and the real culprit is another factor associated with industry activity.”

Until now, several risk factors have been implicated in AML leukemogenesis, but the epidemiologic distribution and precise triggers for AML in Canada had not been fully investigated, the researchers noted.

Recent Videos
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
5 experts in this video
Related Content
Advertisement

EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

Tim Cortese
June 3rd 2025
Article

In patients with advanced Hodgkin lymphoma, BrECADD was noninferior to eBEACOPP chemotherapy and demonstrated improved progression-free survival.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


The FDA assigned a Prescription Drug User Fee Act date of November 30, 2025, for ziftomenib in NPM1-mutant acute myeloid leukemia.

Ziftomenib Earns FDA Priority Review for R/R NPM1-Mutrant AML

Roman Fabbricatore
June 3rd 2025
Article

The FDA assigned a Prescription Drug User Fee Act date of November 30, 2025, for ziftomenib in NPM1-mutant acute myeloid leukemia.


Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.


Low Rates of Chronic Graft-Versus-Host Disease With Ruxolitinib Maintenance Following Allogeneic HCT

Low Rates of Chronic Graft-Versus-Host Disease With Ruxolitinib Maintenance Following Allogeneic HCT

American Society for Transplantation and Cellular Therapy
June 2nd 2025
Article

Researchers conducted a prospective, multicenter phase II clinical trial demonstrating that prolonged administration of ruxolitinib after allogeneic HCT is associated with notably low rates of cGVHD.


Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.

Rusfertide Combo Enhances Responses in Polycythemia Vera

Sabrina Serani
June 2nd 2025
Article

Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.

Related Content
Advertisement

EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

Tim Cortese
June 3rd 2025
Article

In patients with advanced Hodgkin lymphoma, BrECADD was noninferior to eBEACOPP chemotherapy and demonstrated improved progression-free survival.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


The FDA assigned a Prescription Drug User Fee Act date of November 30, 2025, for ziftomenib in NPM1-mutant acute myeloid leukemia.

Ziftomenib Earns FDA Priority Review for R/R NPM1-Mutrant AML

Roman Fabbricatore
June 3rd 2025
Article

The FDA assigned a Prescription Drug User Fee Act date of November 30, 2025, for ziftomenib in NPM1-mutant acute myeloid leukemia.


Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.


Low Rates of Chronic Graft-Versus-Host Disease With Ruxolitinib Maintenance Following Allogeneic HCT

Low Rates of Chronic Graft-Versus-Host Disease With Ruxolitinib Maintenance Following Allogeneic HCT

American Society for Transplantation and Cellular Therapy
June 2nd 2025
Article

Researchers conducted a prospective, multicenter phase II clinical trial demonstrating that prolonged administration of ruxolitinib after allogeneic HCT is associated with notably low rates of cGVHD.


Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.

Rusfertide Combo Enhances Responses in Polycythemia Vera

Sabrina Serani
June 2nd 2025
Article

Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.